Saffron Science

Saffron and Focus

Saffron extract has been studied for cognition in a smaller set of human trials than the mood work. Most of those trials enrolled people with Alzheimer disease or mild cognitive impairment. They measured dementia scales, not a set of everyday attention or processing-speed tasks. One 16-week placebo trial in mild to moderate Alzheimer disease reported better scores than placebo. Comparisons with donepezil and with memantine did not show a clear difference in the scores, and a missing difference is not proof the two are equal. The evidence is earlier, smaller, and more limited than the research on mood.

This room says what those trials measured, what they found, and where the evidence is still thin. It is not medical advice, and it does not recommend saffron for any cognitive condition or as a treatment. Anyone considering saffron for focus or attention should speak with a qualified health professional first.

The aim is the record: what was measured, what the results showed, and what remains uncertain. The fuller mood reading is on saffroncalm.com.

What the trials typically tested

Dementia scales, in people who already had a diagnosis.

The Alzheimer trials used 30 milligrams a day of saffron extract, split as 15 milligrams twice a day. The lengths were 16 weeks, 22 weeks, and 12 months. The people enrolled had probable Alzheimer disease, mild cognitive impairment, or, in one trial, a recent heart bypass. They were not a general group of healthy adults reporting mental fatigue. The measures were the Alzheimer Disease Assessment Scale cognitive subscale, the clinical dementia rating, the mini-mental exam, and, after bypass, a Wechsler memory scale.

Placebo, mild to moderate

One 16-week trial reported better dementia scores than placebo.

Forty-six patients with probable mild to moderate Alzheimer disease were screened for a 16-week double-blind trial. They received 30 milligrams a day, as 15 milligrams twice a day, or placebo. After 16 weeks the paper reports a better outcome than placebo on the cognitive subscale (F = 4.12, P = 0.04) and on the clinical dementia rating (F = 4.12, P = 0.04). Adverse events did not clearly differ. The authors called saffron safe and effective in the short term. This page does not. One small trial is not a treatment, and a dementia scale is not an everyday focus test.

PubMed 20831681

Beside donepezil

Fifty-four adults, 22 weeks, and no proof the two are equal.

Fifty-four adults, 55 or older, with mild to moderate Alzheimer disease were eligible for a 22-week trial of 30 milligrams a day of saffron, again as 15 milligrams twice a day, or donepezil 10 milligrams a day. The authors said saffron was effective in a way similar to donepezil, and they called the evidence preliminary. A 2020 review of the score changes found no significant difference between the groups. Vomiting was more frequent on donepezil. A missing difference in a phase II trial is not proof the two are the same, and it is not a reason to stop donepezil. The paper lists support from Tehran University of Medical Sciences and from a company, Green Plants of Life.

PubMed 19838862 · PubMed 32445136

Beside memantine

Sixty-eight patients, a year, and again no clear gap.

Sixty-eight patients with moderate to severe Alzheimer disease, a mini-mental score of 8 to 14, received memantine 20 milligrams a day or saffron extract 30 milligrams a day for 12 months. The change in the severe cognitive impairment rating did not differ (P = 0.38), and neither did the functional staging score (P = 0.87). Adverse events did not clearly differ. The authors said the year of saffron looked comparable to memantine. Comparable, in a trial of this size, is not proof of equality, and it is not a reason to set memantine down. The authors asked for larger and longer confirmation.

PubMed 25163440

Mild cognitive impairment

A waiting list, not a placebo, and no reported dose in the review.

A single-blind trial followed people with amnestic multi-domain mild cognitive impairment for 12 months. The paper reports 17 people on saffron and 18 on a waiting list. It says mini-mental scores improved on saffron (P = 0.015) while the waiting-list group deteriorated. A 2020 review found no clear difference on the Montreal Cognitive Assessment (P = 0.62). That review could not list a dose for this trial. A waiting list does not show how much of the change was time and attention. This is not a result about ordinary focus.

PubMed 27472878 · PubMed 32445136

After heart surgery

The trial outside the dementia group did not find a difference.

People under 70, after on-pump coronary bypass, with a Wechsler memory score above 70, took 15 milligrams of saffron twice a day or placebo for 12 weeks. The paper reports no significant difference on the memory scale, the mini-mental exam, or the anxiety and depression subscales, and no significant time-by-treatment interaction. The authors said the results do not support a benefit for these bypass-related conditions. A 2020 review counted 55 people in this trial and treated it as the one study in people who were not enrolled for dementia or mild cognitive impairment.

PubMed 29185780 · PubMed 32445136

What is missing

Everyday attention and processing speed were not the tests.

This room did not find a set of randomized trials that measured attention tasks or processing speed in healthy adults and showed a clear benefit. A 2024 review of 46 mixed trials said saffron was more effective than placebo on cognition. The abstract prints numbers for depression, anxiety, and sleep, and it does not print a separate cognition figure. Those 46 trials were not all cognition trials. The authors used the word non-inferior for cognitive disorders. That is the authors speaking. It is not proof of equality. A separate 2024 review of four studies and 118 people looked at saffron in ADHD and called the results promising. That is a diagnosed attention disorder, a different question, and it is not a reason to change a prescribed stimulant.

PubMed 38424688 · PubMed 37864351

Important limits

The cognition set is smaller than the mood set, and the reviews say so.

A hopeful sentence in an abstract is not a settled treatment. These are the constraints the papers and the reviews keep naming.

Fewer trials, and a high risk of bias.

A 2020 review found five randomized trials and 325 people. Four were Alzheimer disease or mild cognitive impairment. The reviewers said the promising results should be read cautiously, because the studies carried a potentially high risk of bias, and they asked for larger trials. Another 2020 review, four trials, said the evidence is not enough to recommend saffron for clinical use in dementia or mild cognitive impairment.

PubMed 32445136 · PubMed 33167948

Small groups, even when a trial ran for a year.

Sixteen weeks, twenty-two weeks, and twelve months are the lengths on the page. Two of them lasted about a year and still enrolled dozens of people, not hundreds. What happens in a broader population, and after the trial stops, is still thinly told.

The extract in the trial is not a handful of threads.

These studies used a prepared saffron extract, weighed in milligrams. Culinary threads were not the material. A result for one extract, in one diagnosis, does not cover every powder with the word saffron on the label.

These findings are not a plan for ordinary focus.

The results belong to people with Alzheimer disease, mild cognitive impairment, or a recent bypass. They do not transfer to a healthy adult who wants a sharper afternoon, and they are not a treatment for a diagnosed attention disorder or for significant cognitive impairment. If you already take donepezil, memantine, a stimulant, or any other medicine, the person who prescribed it has to weigh any extract before it is added, and before anything is stopped.

Practical notes from the research

The trials used an extract. A pinch in the pot is a different material.

Thirty milligrams a day, split as 15 milligrams twice a day, is the amount the Alzheimer trials used. That sentence describes the studies. It is not an amount this page tells you to swallow. The mood trials often used about 28 to 30 milligrams a day of a different standardized extract, and that pattern lives on the calm page. It is not a schedule for cognition.

A kitchen pinch for four people is about a tenth of a gram of whole thread. Dividing that pinch does not turn it into 30 milligrams of extract. The two weights do not convert, because the materials are not the same. Threads in food are for flavor and color. Cooking with threads does not recreate the capsules these trials used.

Any decision to try a supplement belongs with a doctor or a qualified practitioner who knows your health history. The capsule form, read as a study amount, is on saffroncapsules.com. How an extract is standardized is on saffronextractreview.com.

A clear capsule filled with deep red saffron powder.

The trial. Milligrams of extract. Thirty milligrams a day, as 15 milligrams twice a day, in the Alzheimer trials. Not a kitchen pinch.

A different quantity

Not the trial. A pile of raw threads. The studies did not use a pile like this, and the drawing invents no weight.

Two different materials, named in the captions. The picture does not invent a gram.

How to read a paper

Six things worth finding before a cognition score feels like sharper focus.

Randomized. People were assigned by chance, so the two groups started out fair.

A placebo. A lookalike capsule shows how much of the change was time itself. A waiting list is not a placebo.

The dose. How many milligrams, and milligrams of what. One mild-impairment trial did not report a dose in the review table.

The weeks. How long people stayed with it. Scores were read at the end of that stretch.

Who was enrolled. Alzheimer disease, mild impairment, or someone hoping for a sharper ordinary day. Those are different rooms.

The measure. A dementia scale, a memory scale, or an attention task. The name of the test decides what the result can mean.

You do not have to become a researcher to ask these. The parent house walks through the same questions: how the hub reads a paper.

A last word

A score on a dementia scale is not a plan for your afternoon.

What you have read is what happened to groups of people in trials, most of them already living with Alzheimer disease or mild cognitive impairment. You are one person. A change on a research form is not a substitute for care, and it is not a reason to set a prescribed medicine down.

This page is for information only. It is not medical advice, diagnosis, or treatment. Saffron supplements are not intended to diagnose, treat, cure, or prevent any disease. Nothing here stands in for a clinician who knows you. Pregnancy is a reason to skip a supplement. Consult a qualified health professional before use, especially if you are pregnant, nursing, taking medication, or have a medical condition.

If you are thinking about harming yourself, please reach a person. In the United States you can call or text 988, or visit 988lifeline.org. You do not have to sit with that alone.

If a bottle is ever linked from this house, someone will have opened the Amazon or Walmart page first. A future affiliate program may earn a commission from that visit. None is connected today. There is no product on this page, and no price.